Dedicated to translating today’s research into tomorrow’s treatment.
CCRG is a world leader in the field of critical care research and biomedical engineering, with a focus on developing ground-breaking novel technologies and treatments to improve outcomes for the critically ill.
GLOBAL LEADERS IN RESEARCH
We are a dedicated multi-disciplinary group who are not content to just accept good clinical practice, but are driven to develop better technologies, better techniques and better processes that lead to better outcomes for patients.
“We know that quantity of life is not the only important question for our patients, but also quality of life. That is why we are continuously facilitating critical thinking and questioning ‘how can we do better for the patient?” said Group Founder and Director, Professor John Fraser.
Our multi-disciplinary critical care research facility is the largest in Australia, compromising seven purpose-built biology, engineering, and bio-fabrication laboratories. We also have the largest preclinical ICU in the southern hemisphere.
HIGHLIGHTS
In 2022, CCRG had more than 16 studies and trials underway resulting in key highlights including:
Our COVID-19 Critical Care Consortium (COVID Critical) project continued to gain support from sites worldwide. This is the world’s largest known COVID-19 ICU database which now has over 27,000 enrolled patients and collaboration from all seven continents.
Our ‘The Living Heart Project: Hypothermic ex Vivo Perfusion’ (HEVP) started a clinical trial which resulted in 100 per cent success rate for transplanted hearts, including the longest ischemic time and distance travelled by a donated heart. The second phase of this study will commence in 2023.
Our ‘ICU of the Future: Revolutionising the ICU experience for better patient outcomes’ project was unveiled in a world-first space at TPCH with two beds available in our ICU facility.
In another world-first, members of our research team documented how extracorporeal membrane oxygenation (ECMO) – the life-saving blood oxygen therapy – alters the effectiveness of antibiotics in critically ill patients. This breakthrough study is set to change the way ECMO is used and administered and improve outcomes for the health system’s sickest patients.
“For almost 20 years, our research group has remained dedicated to translating today’s research into tomorrow’s treatment.”
The article originally appear in The Prince Charles Hospital’s 2022 Research Report, published with thanks to the generous support of the Study Education Research Trust Account and The Prince Charles Hospital Foundation, via The Common Good. Full version available here.